TITLE

Ofatumumab and Romidepsin

AUTHOR(S)
Augustus, DeAna A.; Blankenship, Patrick S.; Waddell, J. Aubrey; Solimando, Dominic A.
PUB. DATE
May 2010
SOURCE
Hospital Pharmacy;May2010, Vol. 45 Issue 5, p367
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers information on cancer chemotherapy drugs Ofatumumab manufactured as Arzerra by GlaxoSmithKline, and Romidepsin manufactured as Istodax by Gloucester Pharmaceuticals, Inc. Ofatumumab is a monoclonal antibody while Romidepsin is a histone deacetylase inhibitor. Also noted are the drugs' mechanism of action, pharmacokinetics, preparation, stability, administration, and toxicities.
ACCESSION #
51284596

 

Related Articles

  • Bone Loss Due to Cancer Treatment Now Treatable with Prolia.  // Journal of Gerontological Nursing;Nov2011, Vol. 37 Issue 11, p10 

    The article reports on a 2011 decision which the U.S. Food and Drug Administration made to approve the drug denosumab, which is marketed as Prolia. The drug is used to increase bone mass in women at high risk for fracture who are receiving drug therapy for breast cancer and as a treatment to...

  • Targeted Cancer Therapies Part 1 #276. Gharwan, Helen; Groninger, Hunter // Journal of Palliative Medicine;Feb2014, Vol. 17 Issue 2, p236 

    The article looks at the targeted cancer drugs that are commonly used in cancer treatment. These drugs are classified as small molecule drugs, known as tyrosine kinase inhibitors (TKIs) that restrict tyrosine kinases and intracellular enzymes through molecules or pathways needed for normal...

  • Dinutuximab and Panobinostat. Chasick, Ashley; Solimando Jr, Dominic A.; Waddell, J. Aubrey // Hospital Pharmacy;Oct2015, Vol. 50 Issue 9, p767 

    The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

  • No Public Funds or Partners: Can Istodax Be New Approval Model? Morrison, Trista // BioWorld Insight;11/16/2009, Vol. 17 Issue 46, p2 

    The article reports on the approval of Gloucester Pharmaceuticals Inc.'s Istodax (romiepsin) for the treatment of cutaneous T-cell lymphoma by the Food and Drug Administration (FDA) in Cambridge, Massachusetts. Since 2002, it is the first biotechnology firm that gained the approval of FDA...

  • A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. de Graaf, M.; Boven, E.; Oosterhoff, D.; van der Meulen-Muileman, I.H.; Huls, G.A.; Gerritsen, W.R.; Haisma, H.J.; Pinedo, H.M. // British Journal of Cancer;3/4/2002, Vol. 86 Issue 5, p811 

    Monoclonal antibodies against tumour-associated antigens could be useful to deliver enzymes selectively to the site of a tumour for activation of a non-toxic prodrug. A completely human fusion protein may be advantageous for repeated administration, as host immune responses may be avoided. We...

  • WEEK IN REVIEW.  // BioWorld Insight;11/16/2009, Vol. 17 Issue 46, p6 

    The article offers news briefs related to biotechnology in the U.S. PolyMedix Inc. has raised 21 dollars through public offering of stocks and warrants. Astex Therapeutics Ltd. and GlaxoSmithKline PLC has signed the discovery deal worth 500 million dollars. The Food and Drug Administration (FDA)...

  • Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. André, T.; Blons, H.; Mabro, M.; Chibaudel, B.; Bachet, J-B.; Tournigand, C.; Bennamoun, M.; Artru, P.; Nguyen, S.; Ebenezer, C.; Aissat, N.; Cayre, A.; Penault-Llorca, F.; Laurent-Puig, P.; de Gramont, A. // Annals of Oncology;Feb2013, Vol. 24 Issue 2, p412 

    Background The purpose of this study was to evaluate the combination of panitumumab and irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy (oxaliplatin, fluoropyrimidines–irinotecan and bevacizumab). Patients and methods KRAS status...

  • Study on Prescribing Patterns of Monoclonal Antibodies on Cancer Patients in a Teaching Hospital of Central India. Daryani, K. K.; Jaiswal, Mahendra; Rawat, Shyamji; Kuchya, Sachin // International Journal of Pharmaceutical Sciences Review & Resear;Mar/Apr2014, Vol. 25 Issue 2, p237 

    The targeted anti cancer therapies include Monoclonal antibodies and Small molecules, for example tyrosine kinase inhibitors. Biologic therapy with Monoclonal Antibodies includes Rituximab, Trastuzumab, Bevacizumab, Alemtuzumab, Cetuximab, Panitumumab etc. The present study was undertaken to...

  • Target Therapy in Hematological Malignances: New Monoclonal Antibodies. Podhorecka, Monika; Markowicz, Justyna; Szymczyk, Agnieszka; Pawlowski, Johannes // ISRN Otolaryngology;2014, p1 

    Apart from radio- and chemotherapy, monoclonal antibodies (MoAbs) represent a new, more selective tool in the treatment of hematological malignancies. MoAbs bind with the specific antigens of the tumors. This interaction is a basis for targeted therapies which exhibit few side effects and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics